Conjugated To A Detectable Label Or Radioisotope Or Radionuclide Or Heavy Metal-containing Compound Patents (Class 530/391.3)
-
Publication number: 20150079088Abstract: The invention relates generally to multispecific antibodies and to multispecific activatable antibodies that specifically bind to two or more different antigens or epitopes, as well as to methods of making and using these multispecific antibodies and/or multispecific activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.Type: ApplicationFiled: July 25, 2014Publication date: March 19, 2015Inventors: Henry Bernard Lowman, James William West, Sherry Lynn La Porte, Bryan Allen Irving, Daniel Robert Hostetter, Chihunt Wong
-
Publication number: 20150079075Abstract: Provided herein are isolated human, chimeric, and humanized antibodies and antigen-binding fragments thereof that specifically bind to CD11a. Also provided are methods of treating human immunodeficiency virus (e.g., reducing the risk of developing or preventing the development of HIV infection or AIDS) in a subject that has an HIV infection or AIDS that include administering at least one of the antibodies or antigen-binding fragments to the subject. Also provided are methods of crosslinking CD11a on the surface of a cell that include contacting the cell with at least one of the antibodies or antigen-binding fragments. Also provided are compositions (e.g., pharmaceutical compositions) containing at least one of the antibodies or antigen-binding fragments.Type: ApplicationFiled: September 13, 2012Publication date: March 19, 2015Applicant: CytoDyn Inc.Inventors: Richard Trauger, Robert Fleischaker
-
Patent number: 8980265Abstract: Subject matter of the invention are antibody-cytokine fusion proteins having proapoptotic and immune modulating properties, but wherein the cytokine moiety a priori has a bioactivity which is very low or restricted to certain receptor subtypes. These reagent exert their full biological activity via the corresponding cytokine receptor(s) only after antibody-mediated binding of the fusion protein to a specific cell membrane-expressed target molecule. By suitable choice of the antibody specificity, the cytokine activity is directed to the tissue, e.g. tumor tissue, to be treated, and a therapeutic agent can be produced being specifically designed/optimized for the respective indication/tumor entity.Type: GrantFiled: March 14, 2003Date of Patent: March 17, 2015Assignee: BioNTech AGInventors: Klaus Pfizenmaier, Harald Wajant, Dieter Moosmayer, Thomas Wuest
-
Publication number: 20150072885Abstract: A HBS-specific antibody, a LHBS-specific antibody, a WT LHBS-specific antibody, an immunoassay kit comprising the antibodies, and a method of detecting pre-S2 deletion mutant LHBS using the immunoassay kit are disclosed herein. The method comprises incubating a biological sample with a first antibody to captured HBS proteins; detecting the LHBS and WT LHBS bound to the immobilized first antibody, respectively; and calculating the amount of the pre-S2 deletion mutant LHBS protein by subtracting the amount of the WT LHBS protein from that of the LHBS protein. Advantageously, by the method described herein, the amount of the pre-S2 deletion mutant LHBS, a potential high-risk marker for HCC incidence in chronic HBV carriers and recurrence in HCC patients after hepatectomy surgery, in a biological sample may be easily calculated without mutual influence between the WT and pre-S mutant LHBS while reducing the labor-intensive process for cloning each gene product before analysis.Type: ApplicationFiled: July 16, 2014Publication date: March 12, 2015Inventors: Wenya Huang, Ih-Jen Su, Yun-Ping Lee
-
Publication number: 20150071948Abstract: The present invention relates to Fc variants with optimized Fc ligand binding properties, methods for their generation, Fc polypeptides comprising Fc variants with optimized Fc ligand binding properties, and methods for using same.Type: ApplicationFiled: March 13, 2014Publication date: March 12, 2015Inventors: Gregory Alan Lazar, Bassil Dahiyat, Wei Dang, John Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
-
Publication number: 20150072356Abstract: The present invention provides a method for diagnosing venous thromboembolism (VTE), comprising: detecting the level of an integrin ?1 subunit, an integrin ?2 subunit, and/or an integrin ?3 subunit in a blood sample. Also provided is a reagent kit for diagnosing VTE, comprising a substance capable of specifically binding to the integrin ?1 subunit, the integrin ?2 subunit, and/or the integrin ?3 subunit.Type: ApplicationFiled: April 18, 2012Publication date: March 12, 2015Inventor: Lemin Wang
-
Publication number: 20150071923Abstract: Provided herein are modified anti-EGFR antibodies and nucleic acid molecules encoding modified anti-EGFR antibodies. Also provided are methods of treatment and uses using modified anti-EGFR antibodies.Type: ApplicationFiled: September 12, 2014Publication date: March 12, 2015Inventors: Ge Wei, Gregory I. Frost, H. Michael Shepard, Christopher D. Thanos
-
Patent number: 8975036Abstract: The present invention relates to a method for improved diagnosis of dysplasias based on simultaneous detection of INK4a gene products and at least one marker for cell proliferation. Particularly the present invention provides a method for discriminating dysplastic cells over-expressing INK4a gene products from cells over-expressing INK4a gene products without being dysplastic by detection of a marker suitable for characterizing the proliferation properties of the respective cell. The characterization of the proliferation properties may comprise the detection of a marker or a set of markers characteristic for active cell proliferation and/or a marker or a set of markers characteristic for retarded or ceased cell proliferation. The method presented herein thus enables for a specific diagnosis of dysplasias in histological and cytological specimens.Type: GrantFiled: October 29, 2008Date of Patent: March 10, 2015Assignee: Ventana Medical Systems, Inc.Inventors: Ruediger Ridder, Anja Reichert, Marcus Trunk-Gehmacher, Richard Batrla
-
Publication number: 20150065694Abstract: Here, we describe a preassembled plasmonic resonance nanocluster. One embodiment is used for microbe detection and typing. The metallic nanoparticle acceptors with microbe surface antigen epitope, and quantum dot (QD) donors with Fab antibody, are assembled into an immuno-mediated 3D-oriented complex with enhanced energy transfer and fluorescence quenching. The coherent plasmonic resonance between the metal and QD nanoparticles is exploited to achieve improved donor-acceptor resonance within the nanocluster, which in the presence of microbial particles is disassembled in a highly specific manner. The nanocluster provides high detection specificity and sensitivity of the microbes, with a sensitivity limit down to 1-100 particles per microliter and to attomolar levels of a surface antigen epitope. A few specific examples of the plasmonic resonance nanocluster used in microbe detection are disclosed along with ways in which the complex can be easily modified for additional microbes.Type: ApplicationFiled: August 29, 2014Publication date: March 5, 2015Applicant: United States Department of EnergyInventors: Fanqing Frank Chen, Mohamed Shehata Draz
-
Publication number: 20150064179Abstract: Provided is a humanized or chimeric antibody or fragment thereof capable of binding to interleukin-10 (1L-10), wherein said antibody or fragment thereof is capable of being administered to a subject in the absence of an intolerable increase in the level of pro-inflammatory cytokines. Further provided are methods of treatment involving the use of the antibody or fragment thereof.Type: ApplicationFiled: August 29, 2014Publication date: March 5, 2015Inventors: FRANK OSTERROTH, CHRISTOPH UHEREK, CHRISTOPH BRUECHER, PETER RÖTTGEN, BENJAMIN DAELKEN, ANDRÉ ENGLING, CHANTAL ZUBER, NIKLAS CZELOTH, ANDREA WARTENBERG-DEMAND, MARCUS GUTSCHER, JUDITH WESSELS-KRANZ
-
Publication number: 20150064190Abstract: Antibodies that specifically bind to an epitope on the extracellular domain of TEM7R are provided. Nucleic acids encoding such antibodies and cells capable of expressing such antibodies are also provided. The antibodies may be used in methods for treating tumors and for inhibiting angiogenesis in tumors.Type: ApplicationFiled: October 15, 2014Publication date: March 5, 2015Inventors: Hossein Borghaei, Louis M. Weiner
-
Patent number: 8968740Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders. Accordingly, the invention relates to compositions, kits, and methods for diagnosing, prognosing, monitoring, treating and modulating viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders.Type: GrantFiled: November 12, 2010Date of Patent: March 3, 2015Assignees: Dana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital, Inc., Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Fundacion SalesInventors: Margaret A. Shipp, Jing Ouyang, Kunihiko Takeyama, Jeffery L. Kutok, Scott J. Rodig, Gabriel Rabinovich, Diego Omar Croci Russo, Mariana Salatino
-
Publication number: 20150056220Abstract: The present disclosure relates to immunoglobulins and immunoglobulin conjugates with reduced oligomerization and efficient labeling and compositions, methods of generating such immunoglobulins and immunoglobulin conjugates and methods of using such immunoglobulin conjugates particularly in the treatment and prevention of disease.Type: ApplicationFiled: August 1, 2014Publication date: February 26, 2015Applicants: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, NOVARTIS AGInventors: Naresh CHENNAMSETTY, Bernhard HELK, Veysel KAYSER, Bernhardt TROUT, Vladimir VOYNOV
-
Publication number: 20150056134Abstract: The present invention provides compositions for the production of an antibody or functional fragment thereof directed against Sialyl-Lewisa (sLea). The compositions of the invention include polynucleotides encoding a heavy chain and/or a light chain variable domain that binds to sLea. The invention also provides an isolated antibody or functional fragment thereof and methods of treating or preventing a disease, such as cancer or tumor formation, wherein the antibody or functional fragment includes a variable heavy chain domain and a variable light chain domain that has an amino acid sequence provided herein. The invention further provides a conjugate of an antibody or functional fragment thereof conjugated or recombinantly fused to a diagnostic agent, detectable agent or therapeutic agent, and methods of treating, preventing or diagnosing a disease in a subject in need thereof.Type: ApplicationFiled: August 26, 2014Publication date: February 26, 2015Inventors: Ritsuko SAWADA, Shu-Man SUN, Wolfgang SCHOLZ
-
Publication number: 20150056133Abstract: The present invention relates to CX3CR1-targeting imaging agents and their use in treatment and diagnosis of diseases. Single domain CX3CR1-targeting polypeptides linked to detection labels and their use in in vivo imaging of atherosclerotic plaques are described. The CX3CR1-targeting imaging agents are useful in the treatment and diagnosis of CX3CR1-mediated diseases including atherosclerosis.Type: ApplicationFiled: August 20, 2014Publication date: February 26, 2015Inventors: Alisa K. WATERMAN, Nick Mark Devoogdt, Tony Lahoutte, Matthias SCHNEIDER, Sanjaya SINGH, Cedric Jozef Néotère VERVERKEN
-
Publication number: 20150056635Abstract: The present invention is related to the anti-PAX8 antibodies, kits, cocktails, and use of anti-PAX8 antibodies for detection of cancer.Type: ApplicationFiled: October 6, 2014Publication date: February 26, 2015Inventors: Weimin Qi, David Tacha
-
Publication number: 20150056132Abstract: Anti-STEAP-1 antibodies and immunoconjugates thereof are provided. Methods of using anti-STEAP-1 antibodies and immunoconjugates thereof are provided. Methods of detecting or determining the presence of STEAP-1 proteins are provided.Type: ApplicationFiled: May 27, 2014Publication date: February 26, 2015Applicant: Genentech, Inc.Inventors: Mark DENNIS, Jan Marik, Paul Polakis, Bonnee Rubinfeld, Simon Williams
-
Patent number: 8962806Abstract: The present invention comprises a humanized monoclonal antibody that binds to the chemokine receptor CCR4. This antibody is derived from Mab 1567 and recognizes the same epitope. Binding of the invented antibody to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer. Moreover, the antibody is used in combination with vaccines to suppress the activity of regulatory T cells.Type: GrantFiled: December 29, 2008Date of Patent: February 24, 2015Assignees: Dana-Farber Cancer Institute, Inc., The Bingham and Women's HospitalInventors: Wayne Marasco, Jianhua Sui, Quan Zhu, Thomas Kupper
-
Publication number: 20150050215Abstract: The invention provides unique therapeutic and diagnostic antibodies, as well as their fragments, portions, derivatives, and variants thereof, that bind regions of the tau protein that contribute to the initiation and propagation of pathological tau-tau interactions, as well as methods of making them. The invention also relates to methods of using those antibodies for diagnostics, prevention, and treatment of Alzheimer's disease and related tauopathies. The present invention also provides a method for a prophylactic and therapeutic treatment of Alzheimer's disease and other neurodegenerative tauopathies. This method entails the injection of antibodies and/or peptide vaccines that elicits an immune response directed to pathological tau proteins and tau deposits in the brains of patients. Suitable vaccines represent a tau peptide carrying one or more of the tau therapeutic epitopes provided herein.Type: ApplicationFiled: September 14, 2012Publication date: February 19, 2015Applicant: Axon Neuroscience SEInventors: Michal Novak, Eva Kontseková, Branislav Kovácech, Norbert Zilka
-
Publication number: 20150050648Abstract: The present invention provides an external standard in the form of a nucleic acid-antibody complex to be used in a chromatin immunoprecipitation method.Type: ApplicationFiled: November 9, 2012Publication date: February 19, 2015Inventors: Neus VISA, Ann-Kristin ÖSTLUND FARRANTAS, Stefanie Gabriele BÖHM, Andrea EBERLE
-
Publication number: 20150050715Abstract: The present invention concerns methods and compositions for stably tethered structures of defined compositions with multiple functionalities and/or binding specificities. Particular embodiments concern stably tethered structures comprising a homodimer of a first monomer, comprising a dimerization and docking domain attached to a first precursor, and a second monomer comprising an anchoring domain attached to a second precursor. The first and second precursors may be virtually any molecule or structure, such as antibodies, antibody fragments, antibody analogs or mimetics, aptamers, binding peptides, fragments of binding proteins, known ligands for proteins or other molecules, enzymes, detectable labels or tags, therapeutic agents, toxins, pharmaceuticals, cytokines, interleukins, interferons, radioisotopes, proteins, peptides, peptide mimetics, polynucleotides, RNAi, oligosaccharides, natural or synthetic polymeric substances, nanoparticles, quantum dots, organic or inorganic compounds, etc.Type: ApplicationFiled: October 22, 2014Publication date: February 19, 2015Inventors: Chien-Hsing Chang, David M. Goldenberg, William J. McBride, Edmund A. Rossi
-
Publication number: 20150051378Abstract: This invention features methods and compositions useful for treating and diagnosing diseases of the nervous system, retina, skin, muscle, joint, and cartilage using a Dragon family protein. Protein and nucleic acid sequences of human, murine, zebrafish, and C. elegans Dragon family members are also disclosed.Type: ApplicationFiled: June 17, 2014Publication date: February 19, 2015Inventors: Clifford J. Woolf, Tarek A. Samad
-
Publication number: 20150051377Abstract: This invention features methods and compositions useful for treating and diagnosing diseases of the nervous system, retina, skin, muscle, joint, and cartilage using a Dragon family protein. Protein and nucleic acid sequences of human, murine, zebrafish, and C. elegans Dragon family members are also disclosed.Type: ApplicationFiled: June 17, 2014Publication date: February 19, 2015Inventors: Clifford J. Woolf, Tarek A. Samad
-
Patent number: 8956607Abstract: Provided is a humanized or chimeric antibody or fragment thereof capable of binding to interleukin-10 (IL-10), wherein said antibody or fragment thereof: (i) binds to the same region of IL-10 as the IL-10 receptor ?(IL-I10Ra) and is not capable of binding IL-10 when the IL-10 is bound to the IL- 10 receptor; and (ii) binds to IL-10 in homodimeric form by binding a discontinuous epitope comprising residues of both monomers. Further provided are related products and methods involving the use of the antibody or fragment thereof.Type: GrantFiled: November 30, 2010Date of Patent: February 17, 2015Assignee: Biotest AGInventors: Frank Osterroth, Christoph Uherek, Christoph Bruecher, Peter Röttgen, Benjamin Daelken, André Engling, Chantal Zuber, Niklas Czeloth
-
Patent number: 8956811Abstract: The present invention relates to novel antibodies that bind specifically to human Notch 3 and their use in the detection and/or diagnosis of Notch 3 related diseases, such as cancer. The present invention also includes nucleic acids encoding these novel antibodies, vectors and cell lines harboring the nucleic acids, and kits comprising the antibodies for use in the detection and diagnosis.Type: GrantFiled: July 15, 2013Date of Patent: February 17, 2015Assignee: Genentech Inc.Inventors: Kang Li, Sek Chung Fung, Zhengbin Yao
-
Publication number: 20150044208Abstract: The present invention relates to compositions and methods comprising a modified albumin-binding domain to improve the pharmacokinetic properties of therapeutic molecules. The modified peptides show reduced immunogenicity and/or proved solubility. In particular, compositions and methods for enhancing therapeutic potential of protein therapeutics are provided including linking a protein albumin-binding domain, which has been modified to reduce immunogenicity and/or improve solubility, to a therapeutic protein, including therapeutic antibodies, antibody fragments, antibody single domains and/or dimers of antibody single domains. These linked polypeptides can exhibit enhanced serum half life without exacerbated immunogenicity and/or without decreased solubility, and without substantially affecting the specific binding properties of the therapeutic protein.Type: ApplicationFiled: September 19, 2012Publication date: February 12, 2015Applicant: TECHNOPHAGE, INVESTIGAÇÄO E DESENVOLVIMENTO EM BIOTECNOLOGIA, SAInventors: Frederico Nuno Castanheira Aires da Silva, Sofia Volker Côrte-Real, Sara Ferreira Llorente Grancho Lourenço
-
Publication number: 20150044694Abstract: Conjugates of a C-terminal modified diabody and a nanoparticle are provided in which the C-terminal modification introduces a cysteine residue at a C-terminus of the diabody and the diabody is covalently linked to the nanoparticle via a heterobiofunctional linker attached to the introduced cysteine residue.Type: ApplicationFiled: August 11, 2014Publication date: February 12, 2015Inventors: Anna M. WU, Shimon Weiss, Tove Olafsen, Fabien Florent Pinaud, Bhaswati Barat
-
Publication number: 20150044135Abstract: The invention described herein relates to the detection, diagnosis, and treatment of intestinal metaplasias that develop to esophageal, gastric, and pancreatic adenocarcinoma. The stem cells and differentiated cells of these intestinal metaplasias show high expression of CDH17 as well as other proteins. The invention also includes a clonal population of Barrett's esophagus stem cells as well as the stem cells of the surrounding normal epithelia and methods of using them for the detection, diagnosis, and treatment of Barrett's esophagus.Type: ApplicationFiled: September 24, 2014Publication date: February 12, 2015Inventors: Wa Xian, Frank McKeon, Matthew Vincent, Khek Yu Ho
-
Publication number: 20150044704Abstract: The disclosure relates to antibodies to the preferentially expressed antigen in melanoma (PRAME), and the synovial sarcoma X breakpoint 2 (SSX-2) antigens, methods of use, and diagnostic kits thereof. In exemplary embodiments, the disclosure relates to monoclonal antibodies to specific epitopes of the PRAME and SSX-2 antigens and methods of using such antibodies.Type: ApplicationFiled: August 5, 2014Publication date: February 12, 2015Inventors: Nathalie KERTESZ, Sutao ZHU, Chih-Sheng CHIANG
-
Publication number: 20150044233Abstract: Methods for determining the presence of cancer stem cells by detecting GD2 expression. Also provided are methods for reducing proliferation of cancer stem cells by contacting the cells with a GD2 targeting agent, such as an anti-GD2 antibody or a GD3 synthase inhibitor. GD3 synthase inhibitor compounds are also provided.Type: ApplicationFiled: February 27, 2013Publication date: February 12, 2015Inventors: Venkata Battula, Michael Andreeff, Sendurai A. Mani, Tapasree Roy Sarkar
-
Publication number: 20150044137Abstract: Neutralizing antibodies that specifically bind to HIV-1 gp120 and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV infection is disclosed.Type: ApplicationFiled: March 15, 2013Publication date: February 12, 2015Inventors: John R. Mascola, Rebecca M. Lynch, Xueling Wu, Mark Connors, Tongqing Zhou, Joseph Casazza, Peter D. Kwong
-
Patent number: 8952134Abstract: The invention provides hybrid constant regions and antibodies or fusion proteins incorporating the same. The hybrid constant regions include at least CH2 and CH3 regions of an IgG or IgA constant region and C?3 and C?4 regions of a C? constant region. The hybrids retain properties of both component constant regions. The hybrids retain the ability of a C? constant region to form multivalent complexes, e.g., pentameric or hexameric structures. IgG hybrids also retain IgG properties including pH-dependent FcRn binding, which is associated with a relatively long in vivo half-life, and specific binding to protein G, which facilitates purification. Depending on the isotype and subtype, the nature of the antigen and presence of additional IgG CH1 and hinge domains, IgG hybrids may also retain properties of specific binding to protein A, and effector functions ADCC, CDC and opsonization. IgA hybrids retain the property of IgA of binding to an Fc-alpha receptor CD89.Type: GrantFiled: September 26, 2012Date of Patent: February 10, 2015Assignee: JN Biosciences LLCInventors: J. Yun Tso, Naoya Tsurushita
-
Patent number: 8951526Abstract: The present invention provides means and a method assuring the effectiveness of early diagnosis of cancers including gastric cancers. Specifically, the present invention provides an antibody, which is prepared using, as an antigen, (a) a peptide comprising at least contiguous amino acids at positions 69 to 75 in the amino acid sequence of SEQ ID NO: 2, or (b) a peptide consisting of an amino acid sequence in which one or several amino acids are deleted, substituted or added in at least contiguous amino acids at positions 69 to 75 in the amino acid sequence of SEQ ID NO: 2, and having the antigenicity of human MUC1 protein, and which is reactive with human mucin 1 (MUC1) protein.Type: GrantFiled: February 10, 2011Date of Patent: February 10, 2015Assignee: Kagoshima UniversityInventor: Suguru Yonezawa
-
Publication number: 20150037323Abstract: The present invention refers to monoclonal humanized antibodies, which bind to the extracellular domain of the AXL receptor tyrosine kinase and which at least partially inhibit AXL activity.Type: ApplicationFiled: July 15, 2014Publication date: February 5, 2015Applicant: U3 PHARMA GMBHInventors: Peter WIRTZ, Jens RUHE, Takeshi TAKIZAWA, Tomoko TAKAYAMA
-
Publication number: 20150037251Abstract: The invention relates inhibiting nucleic acids directed at mammalian homologues of the Drosophila fwe gene (Flower) and to antibodies against the respective proteins, and their use in diagnosing, preventing and treating cancer.Type: ApplicationFiled: February 18, 2013Publication date: February 5, 2015Applicants: UNIVERSITAT BERN, CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICASInventors: Christa Rhiner, Evgeniya Pertova, Jesus M. Lopez-Gay, Eduardo Moreno
-
Publication number: 20150037364Abstract: Baboon Adenovirus (BaAdV)-2/4 and BaAdV-3 are disclosed herein. BaAdV-2/4 and BaAdV-3 polynucleotide, polypeptides and antibodies that specifically bind BaAdV-2/4 and/or BaAdV-3 are disclosed. Methods are disclosed for detecting BaAdV-2/4 and BaAdV-3. Methods are also disclosed for treating, preventing, and inducing an immune response to BaAdV-2/4 and/or BaAdV-3. Kits are also provided.Type: ApplicationFiled: January 15, 2014Publication date: February 5, 2015Inventors: Charles Chiu, Jean Patterson, Mary Michelle Leland, Kenneth Dee Carey, Dean Ehrdman
-
Publication number: 20150030602Abstract: A novel monoclonal antibody and like antigen-binding molecules against transmembrane protein with EGF-like and two follistatin-like domains 2 (TMEFE2) are provided with unique immunological and biological properties useful in the therapy of affective disorders such as depression and bipolar disorders as well as anxiety disorders. In addition, pharmaceutical compositions and kits comprising such antibody and derivatives thereof are described.Type: ApplicationFiled: January 2, 2013Publication date: January 29, 2015Applicant: PHENOQUEST AGInventors: Ingeborg Sillaber, Marcelo Paez-Pereda
-
Publication number: 20150031861Abstract: The present invention relates to antibodies and antibody fragments, one or more of whose native inter-chain disulfide bridges have been replaced with a specific bridging moiety. The bridging moiety can be selectively targeted to inter-chain disulfide bonds within the antibody or antibody fragment, enabling the construction of more homogenously modified products such as antibody-drug conjugates.Type: ApplicationFiled: March 8, 2013Publication date: January 29, 2015Inventors: Mark Smith, James Baker, Felix Schumacher, Stephen Caddick, Vijay Chudasama, Antoine Maruani
-
Publication number: 20150030535Abstract: Antibodies and meditopes that bind to the antibodies are provided, as well as complexes, compositions and combinations containing the meditopes and antibodies, and methods of producing, using, testing, and screening the same, including therapeutic and diagnostic methods and uses.Type: ApplicationFiled: August 6, 2014Publication date: January 29, 2015Inventors: John C. WILLIAMS, David A. HORNE, Yuelong MA, Heng Wei CHANG, Joshua M. DONALDSON, Cindy ZER, Krzysztof BZYMEK, Kendra N. AVERY, Jun XIE
-
Patent number: 8940276Abstract: Provided are human alpha-synuclein-specific autoantibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for ?-synuclein are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for ?-synuclein targeted immunotherapy and diagnosis, respectively.Type: GrantFiled: December 21, 2009Date of Patent: January 27, 2015Assignees: Biogen Idec International Neuroscience GmbH, University of ZurichInventors: Andreas Weihofen, Jan Grimm, Roger Nitsch, Christoph Hock
-
Patent number: 8940298Abstract: The present invention provides novel high affinity antibodies and fragments thereof that bind to the cancer antigen PSCA. The antibodies of the present invention may be used for cancer diagnosis, prognosis, treatment, visualization, and the like. The present invention also provides methods for the detection, visualization, and treatment of various cancers expressing PSCA.Type: GrantFiled: September 4, 2008Date of Patent: January 27, 2015Assignee: The Regents of the University of CaliforniaInventors: Anna M. Wu, Robert E. Reiter, Eric J. Lepin, James D. Marks, Yu Zhou
-
Patent number: 8940272Abstract: Provided are novel human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.Type: GrantFiled: October 11, 2011Date of Patent: January 27, 2015Assignees: University of Zurich, Biogen Idec International Neuroscience GmbHInventors: Roger Nitsch, Feng Chen, Jan Grimm, Jean-Luc Baeriswyl, Christoph Hock
-
Publication number: 20150024457Abstract: The subject invention relates to antibodies to troponin I as well as methods of use thereof. In particular, such antibodies may be used to detect Troponin I in a patient and may also be used in the diagnosis of, for example, a myocardial infarction or acute coronary syndrome.Type: ApplicationFiled: September 5, 2014Publication date: January 22, 2015Inventors: Susan E. Brophy, Bailin Tu, Joan D. Tyner, Dagang Huang, Robert N. Ziemann
-
Publication number: 20150023968Abstract: An isolated DNA molecule comprising a fragment of the gene encoding the feline NIS is disclosed as well as methods of use thereof. Also provided are methods for rational diet design of food composition suitable for administration to feline companion animals afflicted with hyperthyroidism, comprising (a) accessing at least one database that comprises a first data set relating functional gene profile of a biofluid or tissue sample from an animal to physiological condition of the animal, where the functional gene profile is that of the feline NIS gene; (b) accessing at least one database that comprises a second data set relating effects of bioactive dietary components on the functional gene profile; (c) using an algorithm drawing on these data sets, processing input data defining physiological condition to derive a nutritional formula promoting wellness of a feline companion animal afflicted with hyperthyroidism; and (d) preparing a food composition based on the nutritional formula.Type: ApplicationFiled: December 6, 2012Publication date: January 22, 2015Inventors: Samer Al-Murrani, Jeffrey Brockman
-
Publication number: 20150024459Abstract: The present invention concerns methods and compositions comprising an anti-IGF-1R antibody or fragment thereof for treatment of cancer or autoimmune disease. Preferably, the cancer is renal cell carcinoma, breast cancer or pancreatic cancer. The anti-IGF-1R antibody or fragment may be part of a complex, such as a DOCK-AND-LOCK™ (DNL™) complex. Preferably, the DNL™ complex also comprises a second antibody, a second antibody fragment, an affibody or a cytokine. More preferably, the cytokine is interferon-?2b. Most preferably, the second antibody, second fragment or affibody binds to IGF-1R, TROP2 or CEACAM6. The anti-IGF-1R antibody or complex may be administered alone or in combination with a therapeutic agent, such as an mTOR inhibitor.Type: ApplicationFiled: October 3, 2014Publication date: January 22, 2015Inventors: Chien-Hsing Chang, David M. Goldenberg
-
Publication number: 20150023963Abstract: The present invention provides methods for the expression and/or production of variable domains with a C-terminal extension that can be used for coupling of the variable domain to one or more further groups, residues or moieties. In the method of the invention a yield of at least 80% of variable domains with a cysteine containing C-terminal extension is obtained. Also variable domains are provided and polypeptides comprising one or more variable domains obtainable by the methods of the present invention, as well as compounds that comprise such variable domains and/or polypeptides coupled to one or more groups, residues or moieties.Type: ApplicationFiled: June 20, 2014Publication date: January 22, 2015Applicant: Ablynx N.V.Inventors: Hilde Stals, Veronique De Brabandere, Peter Schotte
-
Publication number: 20150017171Abstract: The present invention relates to methods of diagnosing, and methods of treating, hepatocellular carcinoma in a subject. The invention also relates to polypeptide antagonists of PLVAP proteins, including humanized and chimeric antibodies that specifically bind PLVAP proteins, as well as compositions and kits comprising such polypeptide antagonists.Type: ApplicationFiled: July 21, 2014Publication date: January 15, 2015Inventors: Kuo-Jang Kao, Andrew T. Huang
-
Publication number: 20150017173Abstract: The invention provides human transmembrane proteins (HTMPN) and polynucleotides which identify and encode HTMPN. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of HTMPN.Type: ApplicationFiled: August 28, 2014Publication date: January 15, 2015Applicant: Incyte CorporationInventors: Y. Tom Tang, Preeti G. Lal, Jennifer L. Jackson, Henry Yue, Karl J. Guegler, Neil C. Corley, Olga Bandman, Chandra S. Arvizu, Gina A. Gorgone Simone, Matthew R. Kaser, Mariah R. Baughn, Janice K. Au-Young
-
Publication number: 20150017187Abstract: Provided herein are antibodies comprising multiple non-natural amino acid residues at site-specific positions, compositions comprising the antibodies, methods of their production and methods of their use. The antibodies are useful for methods of treatment and prevention, methods of detection and methods of diagnosis.Type: ApplicationFiled: July 10, 2014Publication date: January 15, 2015Inventors: Christopher D. Thanos, Ramesh Baliga, Kalyani Penta, Avinash Gill, Gang Yin, Erik Zimmerman
-
Publication number: 20150017168Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.Type: ApplicationFiled: July 15, 2014Publication date: January 15, 2015Applicant: ABBVIE INC.Inventors: Tariq Ghayur, Junjian Liu, Gillian A. Kingsbury, Edward B. Reilly, Susan E. Morgan-Lappe